Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Leerink Partnrs

Oruka Therapeutics (NASDAQ:ORKA) was upgraded by Leerink Partnrs to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

Several other research analysts have also weighed in on ORKA. Jefferies Financial Group began coverage on Oruka Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price on the stock. Wedbush assumed coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 target price on the stock. Lifesci Capital started coverage on Oruka Therapeutics in a report on Monday. They issued an “outperform” rating and a $41.00 price target for the company. Leerink Partners began coverage on Oruka Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $44.00 price objective on the stock. Finally, TD Cowen started coverage on Oruka Therapeutics in a research report on Monday. They issued a “buy” rating for the company. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Oruka Therapeutics currently has a consensus rating of “Buy” and an average target price of $41.25.

Oruka Therapeutics Trading Up 2.2 %

Shares of ORKA stock opened at $26.47 on Tuesday. Oruka Therapeutics has a 1-year low of $18.72 and a 1-year high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.